Revenue
2023
2024
2025
Compass Therapeutics, Inc. (CMPX)
Price—Loading quote
Net income
2019
2020
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 · Dec 31 | 2020 · Mar 31 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $850,000 | $0 | — | — | — | — | — |
| Research & development | $56.0M | $42.3M | $38.1M | $30.0M | $20.3M | $14.9M | — | — |
| Operating expenses | $72.8M | $57.5M | $50.4M | $41.7M | $81.9M | $27.8M | — | — |
| Operating income | −$72.8M | −$56.6M | −$50.4M | −$41.7M | −$81.9M | −$27.8M | −$32,105 | −$32,759 |
| EBITDAderived | −$72.6M | −$56.0M | −$49.7M | −$40.9M | −$81.3M | −$25.4M | — | — |
| Net income | −$66.5M | −$49.4M | −$42.5M | −$39.2M | −$82.2M | −$29.5M | −$37,483 | −$36,037 |
| Basic EPSper diluted share | -$0.42 | -$0.36 | -$0.33 | -$0.37 | -$1.31 | -$0.96 | -$0.01 | -$0.01 |
| Diluted EPSper diluted share | — | — | — | — | -$1.31 | -$0.96 | -$0.01 | -$0.01 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 29, 2026Form 4/A | Lerner NeilChief Accounting Officer | BuyCommon Stock | 15.0K | $1.89 | $28.4K | 397.5K |
| Apr 29, 2026Form 4/A | Anderman JonathanGeneral Counsel | BuyCommon Stock | 25.0K | $1.89 | $47.3K | 196.0K |
| May 27, 2025Form 4 | Schuetz Thomas J.CHIEF EXECUTIVE OFFICER | BuyCommon Stock | 10.0K | $2.11 | $21.1K | 6.48M |
| Apr 9, 2025Form 4 | GORDON CARL LDirector,TenPercentOwner | SellCommon Stock · indirect | 3.57M | $1.59 | $5.68M | 0 |
| Apr 9, 2025Form 4 | OrbiMed Capital GP VI LLC +2Director,TenPercentOwner | SellCommon Stock · indirect | 3.57M | $1.59 | $5.68M | 0 |